Establishment Labs Holdings Inc. (NASDAQ:ESTA) Shares Sold by First Turn Management LLC

First Turn Management LLC reduced its stake in shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA) by 3.5% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 357,003 shares of the company’s stock after selling 12,977 shares during the quarter. Establishment Labs comprises approximately 2.4% of First Turn Management LLC’s portfolio, making the stock its 18th largest holding. First Turn Management LLC owned about 1.28% of Establishment Labs worth $15,448,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Healthcare of Ontario Pension Plan Trust Fund acquired a new stake in Establishment Labs during the 1st quarter worth $4,185,000. Divisadero Street Capital Management LP acquired a new position in Establishment Labs in the second quarter valued at $5,829,000. Principal Financial Group Inc. acquired a new position in Establishment Labs in the second quarter valued at $593,000. Bayesian Capital Management LP acquired a new position in Establishment Labs in the first quarter valued at $631,000. Finally, Capital Research Global Investors acquired a new position in Establishment Labs in the first quarter valued at $45,888,000. 72.91% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms have commented on ESTA. BTIG Research lifted their price objective on shares of Establishment Labs from $62.00 to $65.00 and gave the company a “buy” rating in a research note on Monday, October 14th. JPMorgan Chase & Co. dropped their price objective on shares of Establishment Labs from $61.00 to $50.00 and set an “overweight” rating on the stock in a research note on Wednesday, August 7th. Stephens restated an “overweight” rating and issued a $68.00 price objective on shares of Establishment Labs in a research note on Wednesday, August 7th. Finally, Citigroup boosted their price target on shares of Establishment Labs from $45.00 to $50.00 and gave the stock a “neutral” rating in a research note on Tuesday, October 1st. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $60.60.

Establishment Labs Trading Down 0.0 %

Shares of Establishment Labs stock opened at $37.78 on Tuesday. Establishment Labs Holdings Inc. has a 52-week low of $21.25 and a 52-week high of $60.12. The company has a quick ratio of 2.91, a current ratio of 3.62 and a debt-to-equity ratio of 5.94. The company’s 50-day simple moving average is $43.15 and its 200-day simple moving average is $45.55. The firm has a market cap of $1.06 billion, a price-to-earnings ratio of -14.99 and a beta of 1.20.

Establishment Labs Company Profile

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.